Tarsons Products Hits Record ₹124 Cr Revenue in Q2 as Crude Costs Squeeze Margins

Key numbers

Revenue Q2 FY27	₹123.65 Cr20.8% YoY Growth
Market Cap	₹1657.91 CrMedical Equipment
Gross Debt	₹380 CrAs of Sep 2026
RSI	48.27Neutral Zone

Key highlights

• Consolidated revenue reached ₹123.65 crore, a record high and a 20.8% increase over Q2 FY26
• Export revenue grew by 37% during the quarter, supported by wallet share gains with global customers
• Gross margins faced severe pressure due to crude-linked raw material prices surging 30-50% since March 2026
• Operating profit margin stood at 25.14%, partially offset by higher depreciation and finance costs
• Panchla cell culture lines are slated for commercial commissioning in H2 FY27 to complete the current capex cycle

Raw Material Inflation Squeezes Manufacturing Margins

Tarsons Products reported a significant challenge in profitability during the September 2026 quarter, as gross margins contracted by roughly 500 basis points. The management noted that crude-linked raw material prices surged by 30% to 50% following the onset of West Asia geopolitical tensions in March 2026. While the company implemented calibrated price increases, they were insufficient to fully offset the spike in input costs without impacting customer relationships.

Consequently, despite record quarterly revenues of ₹123.65 crore, the company reported a marginal net loss of ₹0.34 crore, contrasted with the year-ago quarter's profitability, as interest and depreciation from new facilities weighed on the bottom line.

Final Phase of ₹400 Crore Capex at Panchla and Amta

• Final commissioning of cell culture lines at the Panchla facility is expected in H2 FY27
• The radiation line and expanded warehousing at the Amta facility are now fully operational
• Standalone standalone revenue potential is estimated at ₹800 crore once full capacity utilization is reached by FY28
• New facilities have added ₹20 crore in estimated annual finance costs and higher depreciation charges
• Current gross debt stands between ₹370 crore and ₹380 crore following the expansion phase
• Export growth of 37% in Q2 FY27 was driven by restocking and new customer inquiries in Europe and the US

Management on Geopolitical Headwinds

Since the onset of the West Asia conflict in March 2026, crude-linked raw material prices have surged between 30 and 50 percent, putting considerable pressure on our gross margins.

Scaling Utilization to Drive Future Operating Leverage

As the company concludes its largest-ever capital expenditure program, focus is shifting from capacity creation to operational efficiency and customer validation for new product lines. Management expects the ₹400 crore investment to translate into meaningful revenue growth starting from FY28. The domestic market continues to see robust demand from the private pharma and healthcare sectors, which grew 19% YoY.

While the government research segment remains slow to recover, the volume growth in consumables helped partially mitigate the impact of higher fixed overheads. Tarsons is now targeting a more balanced international portfolio to reduce reliance on any single geography or large contract.

What to watch next

• Institutional investor meeting in Mumbai scheduled for 18 Nov 2026
• Commercial commissioning of remaining cell culture SKUs at Panchla in H2 FY27
• Normalization of crude-linked raw material prices to recover margins toward 70% level
• Quarterly financial results for the period ending December 31, 2026, expected in Feb 2027

“Higher capacity utilization and improved fixed cost absorption should drive operating leverage, supporting better margins, profitability and return on invested capital.”

“We have deferred government grant of ₹59 crores in our balance sheet and in the P&L we recognize government grant income of ₹8 to ₹9 crores.”

Tarsons Products · financial snapshot

Share price	₹311.6
Market capitalisation	₹1,657.91 Cr
Revenue (annual)	₹422.51 Cr
Net profit (annual)	₹14.32 Cr
Revenue (latest quarter)	₹123.65 Cr+12.16% vs previous quarter
Net profit (latest quarter)	-₹0.34 Cr+76.18% vs previous quarter
P/E (TTM)	223.17×Sector 54.73×
Promoter holding	47.3%0.00% QoQ
FII holding	0.55%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.